drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB08901 | DB13179 | 1,468 | 68 | [
"DDInter1492",
"DDInter1882"
] | Ponatinib | Troleandomycin | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | A macrolide antibiotic that is similar to erythromycin. | Major | 2 | [
[
[
1468,
25,
68
]
],
[
[
1468,
63,
1413
],
[
1413,
23,
68
]
],
[
[
1468,
64,
1101
],
[
1101,
23,
68
]
],
[
[
1468,
63,
309
],
[
309,
... | [
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fexofenadine"
],
[
"Fexofe... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Fexofenadine and Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Ponatinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may ca... |
DB00982 | DB01125 | 1,517 | 279 | [
"DDInter991",
"DDInter98"
] | Isotretinoin | Anisindione | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Moderate | 1 | [
[
[
1517,
24,
279
]
],
[
[
1517,
24,
913
],
[
913,
63,
279
]
],
[
[
1517,
63,
175
],
[
175,
24,
279
]
],
[
[
1517,
64,
1572
],
[
1572,
... | [
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
... | Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone ... |
DB00047 | DB00867 | 176 | 1,052 | [
"DDInter932",
"DDInter1606"
] | Insulin glargine | Ritodrine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Adrenergic beta-agonist used to control premature labor. | Moderate | 1 | [
[
[
176,
24,
1052
]
],
[
[
176,
24,
532
],
[
532,
40,
1052
]
],
[
[
176,
24,
870
],
[
870,
23,
1052
]
],
[
[
176,
24,
708
],
[
708,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine (Compound) resembles Ritodrine (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor inte... |
DB00792 | DB09034 | 832 | 1,313 | [
"DDInter1878",
"DDInter1733"
] | Tripelennamine | Suvorexant | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
832,
24,
1313
]
],
[
[
832,
40,
649
],
[
649,
24,
1313
]
],
[
[
832,
63,
530
],
[
530,
24,
1313
]
],
[
[
832,
24,
100
],
[
100,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a... | Tripelennamine (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction th... |
DB00059 | DB06292 | 1,560 | 549 | [
"DDInter1404",
"DDInter474"
] | Pegaspargase | Dapagliflozin | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
1560,
24,
549
]
],
[
[
1560,
24,
1344
],
[
1344,
40,
549
]
],
[
[
1560,
24,
467
],
[
467,
23,
549
]
],
[
[
1560,
24,
292
],
[
292,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interactio... |
DB08899 | DB09065 | 129 | 760 | [
"DDInter649",
"DDInter424"
] | Enzalutamide | Cobicistat | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
129,
25,
760
]
],
[
[
129,
63,
479
],
[
479,
23,
760
]
],
[
[
129,
24,
1627
],
[
1627,
23,
760
]
],
[
[
129,
62,
271
],
[
271,
2... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepez... | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Canna... |
DB00851 | DB08895 | 611 | 976 | [
"DDInter463",
"DDInter1825"
] | Dacarbazine | Tofacitinib | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
611,
25,
976
]
],
[
[
611,
63,
1461
],
[
1461,
23,
976
]
],
[
[
611,
24,
200
],
[
200,
63,
976
]
],
[
[
611,
24,
1430
],
[
1430,
... | [
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and C... |
DB01059 | DB01278 | 956 | 1,021 | [
"DDInter1313",
"DDInter1506"
] | Norfloxacin | Pramlintide | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
956,
24,
1021
]
],
[
[
956,
40,
1539
],
[
1539,
24,
1021
]
],
[
[
956,
64,
891
],
[
891,
24,
1021
]
],
[
[
956,
25,
1019
],
[
1019,
... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Norfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a modera... | Norfloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Norfloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbat... |
DB00980 | DB08899 | 969 | 129 | [
"DDInter1564",
"DDInter649"
] | Ramelteon | Enzalutamide | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
969,
24,
129
]
],
[
[
969,
6,
8374
],
[
8374,
45,
129
]
],
[
[
969,
21,
28921
],
[
28921,
60,
129
]
],
[
[
969,
24,
1510
],
[
1510,
... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Ramelteon",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Ramelteon (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Ramelteon (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Enzalutamide (Compound)
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and ... |
DB01284 | DB01309 | 1,042 | 1,254 | [
"DDInter1782",
"DDInter933"
] | Tetracosactide | Insulin glulisine | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
1042,
24,
1254
]
],
[
[
1042,
63,
1603
],
[
1603,
24,
1254
]
],
[
[
1042,
62,
480
],
[
480,
24,
1254
]
],
[
[
1042,
24,
1592
],
[
1592... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
... | Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Formoterol... |
DB09280 | DB11921 | 1,604 | 1,019 | [
"DDInter1101",
"DDInter492"
] | Lumacaftor | Deflazacort | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
1604,
25,
1019
]
],
[
[
1604,
24,
192
],
[
192,
24,
1019
]
],
[
[
1604,
64,
629
],
[
629,
24,
1019
]
],
[
[
1604,
25,
1375
],
[
1375,
... | [
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
],
[
... | Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens and Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Lumacaftor may lead to a major life threatening interaction when taken with Sirolimus and S... |
DB01033 | DB08880 | 328 | 1,510 | [
"DDInter1156",
"DDInter1771"
] | Mercaptopurine | Teriflunomide | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
328,
25,
1510
]
],
[
[
328,
63,
1461
],
[
1461,
23,
1510
]
],
[
[
328,
24,
221
],
[
221,
63,
1510
]
],
[
[
328,
24,
1136
],
[
1136,
... | [
[
[
"Mercaptopurine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus typ... |
DB06228 | DB11901 | 792 | 913 | [
"DDInter1609",
"DDInter107"
] | Rivaroxaban | Apalutamide | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
792,
25,
913
]
],
[
[
792,
64,
279
],
[
279,
24,
913
]
],
[
[
792,
63,
600
],
[
600,
24,
913
]
],
[
[
792,
24,
1320
],
[
1320,
6... | [
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
],
[
"Anisindione",
"... | Rivaroxaban may lead to a major life threatening interaction when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may... |
DB01254 | DB09154 | 1,213 | 1,475 | [
"DDInter484",
"DDInter1686"
] | Dasatinib | Sodium citrate | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
1213,
24,
1475
]
],
[
[
1213,
24,
263
],
[
263,
23,
1475
]
],
[
[
1213,
63,
355
],
[
355,
23,
1475
]
],
[
[
1213,
25,
1468
],
[
1468,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
],
[
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib and Axitinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose m... |
DB01181 | DB11859 | 1,532 | 418 | [
"DDInter906",
"DDInter230"
] | Ifosfamide | Brexanolone | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depr... | Moderate | 1 | [
[
[
1532,
24,
418
]
],
[
[
1532,
24,
820
],
[
820,
24,
418
]
],
[
[
1532,
63,
100
],
[
100,
24,
418
]
],
[
[
1532,
64,
770
],
[
770,
... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine an... |
DB01166 | DB14881 | 477 | 180 | [
"DDInter379",
"DDInter1329"
] | Cilostazol | Oliceridine | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
477,
24,
180
]
],
[
[
477,
62,
112
],
[
112,
23,
180
]
],
[
[
477,
63,
401
],
[
401,
24,
180
]
],
[
[
477,
24,
124
],
[
124,
24,... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and P... |
DB00241 | DB00281 | 288 | 608 | [
"DDInter257",
"DDInter1066"
] | Butalbital | Lidocaine | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication . In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anes... | Minor | 0 | [
[
[
288,
23,
608
]
],
[
[
288,
23,
1101
],
[
1101,
62,
608
]
],
[
[
288,
24,
868
],
[
868,
62,
608
]
],
[
[
288,
1,
536
],
[
536,
62... | [
[
[
"Butalbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
]
],
[
[
"Butalbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"... | Butalbital may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafeni... |
DB01764 | DB08865 | 805 | 1,593 | [
"DDInter469",
"DDInter448"
] | Dalfopristin | Crizotinib | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
805,
24,
1593
]
],
[
[
805,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
805,
23,
283
],
[
283,
62,
1593
]
],
[
[
805,
63,
883
],
[
883,
... | [
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Dalfopristin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Dalfopristin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Dalfopristin may c... |
DB00445 | DB01166 | 322 | 477 | [
"DDInter655",
"DDInter379"
] | Epirubicin | Cilostazol | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
322,
24,
477
]
],
[
[
322,
18,
6509
],
[
6509,
57,
477
]
],
[
[
322,
7,
9866
],
[
9866,
57,
477
]
],
[
[
322,
21,
28892
],
[
28892,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Epirubicin",
"{u} (Compound) downregulates {v} (Gene)",
"EIF5"
],
[
"EIF5",
"{u} (Gene) is downregulated by {v} ... | Epirubicin (Compound) downregulates EIF5 (Gene) and EIF5 (Gene) is downregulated by Cilostazol (Compound)
Epirubicin (Compound) upregulates LAP3 (Gene) and LAP3 (Gene) is downregulated by Cilostazol (Compound)
Epirubicin (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Cilost... |
DB00938 | DB12245 | 455 | 823 | [
"DDInter1635",
"DDInter1863"
] | Salmeterol | Triclabendazole | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
455,
24,
823
]
],
[
[
455,
24,
1612
],
[
1612,
24,
823
]
],
[
[
455,
63,
1010
],
[
1010,
24,
823
]
],
[
[
455,
64,
1622
],
[
1622,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and... |
DB00365 | DB06616 | 839 | 594 | [
"DDInter842",
"DDInter224"
] | Grepafloxacin | Bosutinib | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
839,
24,
594
]
],
[
[
839,
23,
112
],
[
112,
23,
594
]
],
[
[
839,
24,
1559
],
[
1559,
24,
594
]
],
[
[
839,
24,
460
],
[
460,
6... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and... |
DB00601 | DB01097 | 453 | 1,377 | [
"DDInter1073",
"DDInter1033"
] | Linezolid | Leflunomide | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
453,
25,
1377
]
],
[
[
453,
18,
18226
],
[
18226,
57,
1377
]
],
[
[
453,
21,
29062
],
[
29062,
60,
1377
]
],
[
[
453,
24,
126
],
[
126... | [
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Linezolid",
"{u} (Compound) downregulates {v} (Gene)",
"GDF15"
],
[
"GDF15",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Linezolid (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Leflunomide (Compound)
Linezolid (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Compound)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Wa... |
DB00341 | DB11732 | 1,242 | 1,097 | [
"DDInter343",
"DDInter1027"
] | Cetirizine | Lasmiditan | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
1242,
24,
1097
]
],
[
[
1242,
74,
701
],
[
701,
24,
1097
]
],
[
[
1242,
24,
1614
],
[
1614,
24,
1097
]
],
[
[
1242,
40,
1413
],
[
1413... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Cetirizine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken w... | Cetirizine (Compound) resembles Clemastine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Cetirizine may cause a moderate interaction that could... |
DB00741 | DB11248 | 167 | 1,193 | [
"DDInter885",
"DDInter1965"
] | Hydrocortisone | Zinc gluconate | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Minor | 0 | [
[
[
167,
23,
1193
]
],
[
[
167,
24,
1531
],
[
1531,
23,
1193
]
],
[
[
167,
24,
270
],
[
270,
62,
1193
]
],
[
[
167,
63,
66
],
[
66,
... | [
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizum... |
DB01309 | DB11071 | 1,254 | 1,004 | [
"DDInter933",
"DDInter1449"
] | Insulin glulisine | Phenyl salicylate | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in ). Phenyl salicylate ma... | Moderate | 1 | [
[
[
1254,
24,
1004
]
],
[
[
1254,
63,
1411
],
[
1411,
24,
1004
]
],
[
[
1254,
24,
877
],
[
877,
63,
1004
]
],
[
[
1254,
63,
1411
],
[
1411... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbut... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00673 | DB08864 | 723 | 786 | [
"DDInter112",
"DDInter1595"
] | Aprepitant | Rilpivirine | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
723,
24,
786
]
],
[
[
723,
24,
655
],
[
655,
1,
786
]
],
[
[
723,
6,
8374
],
[
8374,
45,
786
]
],
[
[
723,
21,
29343
],
[
29343,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Aprepitant (Compound) causes Blood creatinine increased (Side Ef... |
DB08882 | DB12095 | 1,281 | 179 | [
"DDInter1070",
"DDInter1760"
] | Linagliptin | Telotristat ethyl | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin w... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
1281,
24,
179
]
],
[
[
1281,
24,
214
],
[
214,
24,
179
]
],
[
[
1281,
63,
175
],
[
175,
24,
179
]
],
[
[
1281,
64,
1101
],
[
1101,
... | [
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
... | Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Triamcin... |
DB00939 | DB01191 | 1,338 | 1,039 | [
"DDInter1135",
"DDInter518"
] | Meclofenamic acid | Dexfenfluramine | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Moderate | 1 | [
[
[
1338,
24,
1039
]
],
[
[
1338,
24,
1046
],
[
1046,
63,
1039
]
],
[
[
1338,
25,
500
],
[
500,
63,
1039
]
],
[
[
1338,
63,
702
],
[
702,
... | [
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplaciz... | Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Meclofenamic acid may lead to a major life threatening interaction when taken with Enoxaparin an... |
DB00014 | DB09104 | 521 | 286 | [
"DDInter839",
"DDInter1118"
] | Goserelin | Magnesium hydroxide | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
521,
24,
286
]
],
[
[
521,
24,
820
],
[
820,
23,
286
]
],
[
[
521,
24,
859
],
[
859,
24,
286
]
],
[
[
521,
25,
494
],
[
494,
24,... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole a... |
DB08875 | DB15982 | 1,618 | 1,339 | [
"DDInter262",
"DDInter193"
] | Cabozantinib | Berotralstat | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Major | 2 | [
[
[
1618,
25,
1339
]
],
[
[
1618,
63,
1101
],
[
1101,
23,
1339
]
],
[
[
1618,
24,
283
],
[
283,
23,
1339
]
],
[
[
1618,
63,
761
],
[
761,
... | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexa... | Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fe... |
DB01603 | DB09268 | 1,366 | 1,662 | [
"DDInter1195",
"DDInter1464"
] | Meticillin | Picosulfuric acid | One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1366,
24,
1662
]
],
[
[
1366,
63,
597
],
[
597,
24,
1662
]
],
[
[
1366,
1,
319
],
[
319,
24,
1662
]
],
[
[
1366,
40,
339
],
[
339,
... | [
[
[
"Meticillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Meticillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
... | Meticillin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Meticillin (Compound) resembles Amoxicillin (Compound) and Amoxicillin may cause a moderate int... |
DB06589 | DB11627 | 1,250 | 1,367 | [
"DDInter1400",
"DDInter860"
] | Pazopanib | Hepatitis B Vaccine (Recombinant) | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
1250,
24,
1367
]
],
[
[
1250,
63,
1560
],
[
1560,
24,
1367
]
],
[
[
1250,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
1250,
25,
375
],
[
375... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegasp... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Pazopanib may lead to a major life threatening interaction when taken with Cladribine ... |
DB00304 | DB06206 | 1,657 | 1,268 | [
"DDInter508",
"DDInter1719"
] | Desogestrel | Sugammadex | Desogestrel, a prodrug, is a third generation progestogen and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activ... | Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general ane... | Major | 2 | [
[
[
1657,
25,
1268
]
],
[
[
1657,
1,
615
],
[
615,
64,
1268
]
],
[
[
1657,
1,
1336
],
[
1336,
25,
1268
]
],
[
[
1657,
1,
615
],
[
615,
... | [
[
[
"Desogestrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sugammadex"
]
],
[
[
"Desogestrel",
"{u} (Compound) resembles {v} (Compound)",
"Norelgestromin"
],
[
"Norelgestromin",
"{u} may lead to a major life... | Desogestrel (Compound) resembles Norelgestromin (Compound) and Norelgestromin may lead to a major life threatening interaction when taken with Sugammadex
Desogestrel (Compound) resembles Etonogestrel (Compound) and Etonogestrel may lead to a major life threatening interaction when taken with Sugammadex
Desogestrel (Com... |
DB01229 | DB09048 | 973 | 555 | [
"DDInter1378",
"DDInter1284"
] | Paclitaxel (protein-bound) | Netupitant | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Moderate | 1 | [
[
[
973,
24,
555
]
],
[
[
973,
63,
1101
],
[
1101,
23,
555
]
],
[
[
973,
24,
283
],
[
283,
62,
555
]
],
[
[
973,
63,
63
],
[
63,
24,... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Paclitaxel m... |
DB00728 | DB01233 | 1,610 | 1,311 | [
"DDInter1612",
"DDInter1197"
] | Rocuronium | Metoclopramide | Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechan... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1610,
24,
1311
]
],
[
[
1610,
6,
17589
],
[
17589,
45,
1311
]
],
[
[
1610,
21,
28680
],
[
28680,
60,
1311
]
],
[
[
1610,
24,
1620
],
[
... | [
[
[
"Rocuronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Rocuronium",
"{u} (Compound) binds {v} (Gene)",
"HTR3A"
],
[
"HTR3A",
"{u} (Gene) is bound by {v} (Compound)... | Rocuronium (Compound) binds HTR3A (Gene) and HTR3A (Gene) is bound by Metoclopramide (Compound)
Rocuronium (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Metoclopramide (Compound)
Rocuronium may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetrac... |
DB10343 | DB11834 | 962 | 1,303 | [
"DDInter160",
"DDInter849"
] | Bacillus calmette-guerin substrain tice live antigen | Guselkumab | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Major | 2 | [
[
[
962,
25,
1303
]
],
[
[
962,
64,
713
],
[
713,
24,
1303
]
],
[
[
962,
25,
270
],
[
270,
63,
1303
]
],
[
[
962,
25,
1456
],
[
1456,
... | [
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guselkumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction wh... | Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Bacillus calmette-guerin substrain tice live antigen may lead to a majo... |
DB00973 | DB06595 | 1,149 | 1,491 | [
"DDInter707",
"DDInter1214"
] | Ezetimibe | Midostaurin | Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal vill... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
1149,
24,
1491
]
],
[
[
1149,
24,
927
],
[
927,
63,
1491
]
],
[
[
1149,
63,
467
],
[
467,
24,
1491
]
],
[
[
1149,
24,
72
],
[
72,
... | [
[
[
"Ezetimibe",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Ezetimibe",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Ezetimibe may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Ezetimibe may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simv... |
DB00029 | DB00176 | 25 | 529 | [
"DDInter99",
"DDInter770"
] | Anistreplase | Fluvoxamine | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Moderate | 1 | [
[
[
25,
24,
529
]
],
[
[
25,
24,
1274
],
[
1274,
63,
529
]
],
[
[
25,
25,
1172
],
[
1172,
24,
529
]
],
[
[
25,
25,
1421
],
[
1421,
6... | [
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Anistreplase may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ib... |
DB00451 | DB01255 | 542 | 633 | [
"DDInter1064",
"DDInter1078"
] | Levothyroxine | Lisdexamfetamine | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Moderate | 1 | [
[
[
542,
24,
633
]
],
[
[
542,
63,
80
],
[
80,
40,
633
]
],
[
[
542,
24,
1529
],
[
1529,
1,
633
]
],
[
[
542,
23,
1523
],
[
1523,
40... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
... | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Lisdexamfetamine (Compound)
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Li... |
DB04946 | DB06603 | 924 | 39 | [
"DDInter907",
"DDInter1387"
] | Iloperidone | Panobinostat | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
924,
25,
39
]
],
[
[
924,
62,
112
],
[
112,
23,
39
]
],
[
[
924,
63,
272
],
[
272,
24,
39
]
],
[
[
924,
24,
1478
],
[
1478,
63,
... | [
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Iloperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Iloperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramin... |
DB00398 | DB01394 | 79 | 1,554 | [
"DDInter1702",
"DDInter431"
] | Sorafenib | Colchicine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Major | 2 | [
[
[
79,
25,
1554
]
],
[
[
79,
6,
3486
],
[
3486,
45,
1554
]
],
[
[
79,
18,
16974
],
[
16974,
46,
1554
]
],
[
[
79,
7,
5776
],
[
5776,
... | [
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Colchicine"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Colchicin... | Sorafenib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Colchicine (Compound)
Sorafenib (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is upregulated by Colchicine (Compound)
Sorafenib (Compound) upregulates LONP1 (Gene) and LONP1 (Gene) is upregulated by Colchicine (Compound)
Sorafenib (Compound... |
DB12500 | DB14761 | 283 | 242 | [
"DDInter714",
"DDInter1578"
] | Fedratinib | Remdesivir | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
283,
24,
242
]
],
[
[
283,
63,
467
],
[
467,
24,
242
]
],
[
[
283,
64,
1377
],
[
1377,
24,
242
]
],
[
[
283,
62,
351
],
[
351,
2... | [
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
... | Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Fedratinib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may ca... |
DB00281 | DB00501 | 608 | 752 | [
"DDInter1066",
"DDInter380"
] | Lidocaine | Cimetidine | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Moderate | 1 | [
[
[
608,
24,
752
]
],
[
[
608,
6,
21998
],
[
21998,
45,
752
]
],
[
[
608,
21,
29551
],
[
29551,
60,
752
]
],
[
[
608,
23,
510
],
[
510,
... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by ... | Lidocaine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Cimetidine (Compound)
Lidocaine (Compound) causes Block heart (Side Effect) and Block heart (Side Effect) is caused by Cimetidine (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Al... |
DB00046 | DB01278 | 1,179 | 1,021 | [
"DDInter940",
"DDInter1506"
] | Insulin lispro | Pramlintide | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1179,
24,
1021
]
],
[
[
1179,
23,
1103
],
[
1103,
23,
1021
]
],
[
[
1179,
24,
1560
],
[
1560,
24,
1021
]
],
[
[
1179,
25,
839
],
[
839... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
... | Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Pramlintide
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and... |
DB01233 | DB09068 | 1,311 | 1,427 | [
"DDInter1197",
"DDInter1948"
] | Metoclopramide | Vortioxetine | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
1311,
24,
1427
]
],
[
[
1311,
62,
1479
],
[
1479,
24,
1427
]
],
[
[
1311,
63,
1532
],
[
1532,
24,
1427
]
],
[
[
1311,
24,
1670
],
[
16... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Metoclopramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic aci... | Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Metoclopramide may cause a moderate interaction that could exacerbate diseases when take... |
DB00682 | DB00994 | 126 | 361 | [
"DDInter1951",
"DDInter1277"
] | Warfarin | Neomycin | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Moderate | 1 | [
[
[
126,
24,
361
]
],
[
[
126,
62,
1647
],
[
1647,
24,
361
]
],
[
[
126,
24,
101
],
[
101,
63,
361
]
],
[
[
126,
63,
277
],
[
277,
2... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acarbose"
],
[
"Acarb... | Warfarin may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Neomycin
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazo... |
DB00046 | DB01083 | 1,179 | 1,142 | [
"DDInter940",
"DDInter1348"
] | Insulin lispro | Orlistat | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Moderate | 1 | [
[
[
1179,
24,
1142
]
],
[
[
1179,
24,
5
],
[
5,
63,
1142
]
],
[
[
1179,
24,
1324
],
[
1324,
24,
1142
]
],
[
[
1179,
63,
305
],
[
305,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone ... |
DB00450 | DB00637 | 78 | 1,557 | [
"DDInter603",
"DDInter128"
] | Droperidol | Astemizole | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Major | 2 | [
[
[
78,
25,
1557
]
],
[
[
78,
40,
11482
],
[
11482,
40,
1557
]
],
[
[
78,
40,
1568
],
[
1568,
64,
1557
]
],
[
[
78,
6,
3958
],
[
3958,
... | [
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Astemizole"
]
],
[
[
"Droperidol",
"{u} (Compound) resembles {v} (Compound)",
"Fluspirilene"
],
[
"Fluspirilene",
"{u} (Compound) resembles {v} (Comp... | Droperidol (Compound) resembles Fluspirilene (Compound) and Fluspirilene (Compound) resembles Astemizole (Compound)
Droperidol (Compound) resembles Pimozide (Compound) and Pimozide may lead to a major life threatening interaction when taken with Astemizole
Droperidol (Compound) binds KCNH2 (Gene) and KCNH2 (Gene) is bo... |
DB01155 | DB01276 | 872 | 123 | [
"DDInter813",
"DDInter706"
] | Gemifloxacin | Exenatide | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
872,
24,
123
]
],
[
[
872,
64,
1573
],
[
1573,
24,
123
]
],
[
[
872,
40,
1539
],
[
1539,
24,
123
]
],
[
[
872,
24,
820
],
[
820,
... | [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisone"
],
[
"Prednis... | Gemifloxacin may lead to a major life threatening interaction when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Gemifloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate di... |
DB00402 | DB06282 | 1,407 | 516 | [
"DDInter685",
"DDInter1053"
] | Eszopiclone | Levocetirizine | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1407,
24,
516
]
],
[
[
1407,
63,
701
],
[
701,
24,
516
]
],
[
[
1407,
24,
1614
],
[
1614,
24,
516
]
],
[
[
1407,
24,
407
],
[
407,
... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Na... |
DB00656 | DB08875 | 827 | 1,618 | [
"DDInter1851",
"DDInter262"
] | Trazodone | Cabozantinib | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
827,
25,
1618
]
],
[
[
827,
23,
112
],
[
112,
23,
1618
]
],
[
[
827,
24,
723
],
[
723,
24,
1618
]
],
[
[
827,
24,
384
],
[
384,
... | [
[
[
"Trazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Trazodone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Trazodone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Apre... |
DB00374 | DB00975 | 1,061 | 1,317 | [
"DDInter1852",
"DDInter573"
] | Treprostinil | Dipyridamole | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Moderate | 1 | [
[
[
1061,
24,
1317
]
],
[
[
1061,
7,
7067
],
[
7067,
45,
1317
]
],
[
[
1061,
21,
28956
],
[
28956,
60,
1317
]
],
[
[
1061,
23,
944
],
[
94... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Treprostinil",
"{u} (Compound) upregulates {v} (Gene)",
"PDE1A"
],
[
"PDE1A",
"{u} (Gene) is bound by {v} (C... | Treprostinil (Compound) upregulates PDE1A (Gene) and PDE1A (Gene) is bound by Dipyridamole (Compound)
Treprostinil (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Dipyridamole (Compound)
Treprostinil may cause a minor interaction that can limit clinical effects when taken with C... |
DB01128 | DB01268 | 918 | 1,151 | [
"DDInter204",
"DDInter1731"
] | Bicalutamide | Sunitinib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
918,
24,
1151
]
],
[
[
918,
6,
8374
],
[
8374,
45,
1151
]
],
[
[
918,
21,
29269
],
[
29269,
60,
1151
]
],
[
[
918,
62,
1247
],
[
1247,... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Bicalutamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Bicalutamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Bicalutamide (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Sunitinib (Compound)
Bicalutamide may cause a minor interaction that can limit clinical effects when taken wi... |
DB05316 | DB11730 | 749 | 351 | [
"DDInter1467",
"DDInter1588"
] | Pimavanserin | Ribociclib | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
749,
24,
351
]
],
[
[
749,
62,
112
],
[
112,
23,
351
]
],
[
[
749,
63,
355
],
[
355,
24,
351
]
],
[
[
749,
24,
951
],
[
951,
24,... | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Pimavanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and L... |
DB00220 | DB01190 | 798 | 568 | [
"DDInter1276",
"DDInter398"
] | Nelfinavir | Clindamycin | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Moderate | 1 | [
[
[
798,
24,
568
]
],
[
[
798,
6,
8374
],
[
8374,
45,
568
]
],
[
[
798,
21,
29278
],
[
29278,
60,
568
]
],
[
[
798,
24,
609
],
[
609,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Nelfinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clindamycin (Compound)
Nelfinavir (Compound) causes Inflammation (Side Effect) and Inflammation (Side Effect) is caused by Clindamycin (Compound)
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Clarithromy... |
DB08880 | DB12332 | 1,510 | 1,619 | [
"DDInter1771",
"DDInter1626"
] | Teriflunomide | Rucaparib | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
1510,
25,
1619
]
],
[
[
1510,
63,
112
],
[
112,
23,
1619
]
],
[
[
1510,
64,
259
],
[
259,
24,
1619
]
],
[
[
1510,
63,
969
],
[
969,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Me... | Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Teriflunomide may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept m... |
DB00285 | DB06209 | 1,100 | 256 | [
"DDInter1927",
"DDInter1508"
] | Venlafaxine | Prasugrel | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Moderate | 1 | [
[
[
1100,
24,
256
]
],
[
[
1100,
6,
10215
],
[
10215,
45,
256
]
],
[
[
1100,
21,
28681
],
[
28681,
60,
256
]
],
[
[
1100,
23,
752
],
[
752... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Venlafaxine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound... | Venlafaxine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Prasugrel (Compound)
Venlafaxine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Cime... |
DB00771 | DB00777 | 262 | 146 | [
"DDInter397",
"DDInter1537"
] | Clidinium | Propiomazine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Moderate | 1 | [
[
[
262,
24,
146
]
],
[
[
262,
63,
508
],
[
508,
1,
146
]
],
[
[
262,
24,
401
],
[
401,
63,
146
]
],
[
[
262,
24,
1178
],
[
1178,
1,... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that cou... |
DB00067 | DB00531 | 317 | 450 | [
"DDInter1921",
"DDInter456"
] | Vasopressin | Cyclophosphamide | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Moderate | 1 | [
[
[
317,
24,
450
]
],
[
[
317,
25,
1593
],
[
1593,
63,
450
]
],
[
[
317,
23,
112
],
[
112,
63,
450
]
],
[
[
317,
24,
51
],
[
51,
63,... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
]
],
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Cr... | Vasopressin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide
Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazol... |
DB00204 | DB09104 | 228 | 286 | [
"DDInter580",
"DDInter1118"
] | Dofetilide | Magnesium hydroxide | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
228,
24,
286
]
],
[
[
228,
25,
820
],
[
820,
23,
286
]
],
[
[
228,
24,
1559
],
[
1559,
23,
286
]
],
[
[
228,
24,
688
],
[
688,
2... | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"... | Dofetilide may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine m... |
DB00532 | DB00835 | 208 | 100 | [
"DDInter1152",
"DDInter245"
] | Mephenytoin | Brompheniramine | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
208,
24,
100
]
],
[
[
208,
24,
832
],
[
832,
24,
100
]
],
[
[
208,
63,
128
],
[
128,
24,
100
]
],
[
[
208,
24,
649
],
[
649,
63,... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Dexbro... |
DB00363 | DB01254 | 695 | 1,213 | [
"DDInter419",
"DDInter484"
] | Clozapine | Dasatinib | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
695,
25,
1213
]
],
[
[
695,
6,
10509
],
[
10509,
45,
1213
]
],
[
[
695,
18,
17366
],
[
17366,
46,
1213
]
],
[
[
695,
7,
16703
],
[
167... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"CYP1B1"
],
[
"CYP1B1",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"... | Clozapine (Compound) binds CYP1B1 (Gene) and CYP1B1 (Gene) is bound by Dasatinib (Compound)
Clozapine (Compound) downregulates C2CD5 (Gene) and C2CD5 (Gene) is upregulated by Dasatinib (Compound)
Clozapine (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is upregulated by Dasatinib (Compound)
Clozapine (Compoun... |
DB04908 | DB11967 | 1,671 | 710 | [
"DDInter741",
"DDInter210"
] | Flibanserin | Binimetinib | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
1671,
24,
710
]
],
[
[
1671,
25,
1593
],
[
1593,
24,
710
]
],
[
[
1671,
24,
951
],
[
951,
24,
710
]
],
[
[
1671,
24,
1619
],
[
1619,
... | [
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Flibanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizoti... | Flibanserin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may c... |
DB00970 | DB01041 | 0 | 770 | [
"DDInter466",
"DDInter1789"
] | Dactinomycin | Thalidomide | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
0,
25,
770
]
],
[
[
0,
7,
2637
],
[
2637,
45,
770
]
],
[
[
0,
18,
7669
],
[
7669,
46,
770
]
],
[
[
0,
18,
20113
],
[
20113,
57,
... | [
[
[
"Dactinomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Dactinomycin",
"{u} (Compound) upregulates {v} (Gene)",
"FGFR2"
],
[
"FGFR2",
"{u} (Gene) is bound by {v} (Compound)",
... | Dactinomycin (Compound) upregulates FGFR2 (Gene) and FGFR2 (Gene) is bound by Thalidomide (Compound)
Dactinomycin (Compound) downregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Thalidomide (Compound)
Dactinomycin (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Thalidomide (Compound)
D... |
DB00661 | DB09330 | 122 | 985 | [
"DDInter1928",
"DDInter1352"
] | Verapamil | Osimertinib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
122,
24,
985
]
],
[
[
122,
25,
1478
],
[
1478,
24,
985
]
],
[
[
122,
25,
119
],
[
119,
63,
985
]
],
[
[
122,
24,
1040
],
[
1040,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
... | Verapamil may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Verapamil may lead to a major life threatening interaction when taken with Talazoparib and Talazoparib may cause a moderate inter... |
DB00860 | DB01144 | 891 | 1,326 | [
"DDInter1513",
"DDInter540"
] | Prednisolone | Diclofenamide | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Moderate | 1 | [
[
[
891,
24,
1326
]
],
[
[
891,
24,
504
],
[
504,
1,
1326
]
],
[
[
891,
24,
359
],
[
359,
40,
1326
]
],
[
[
891,
21,
28769
],
[
28769,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound)... |
DB00277 | DB08880 | 1,031 | 1,510 | [
"DDInter1791",
"DDInter1771"
] | Theophylline | Teriflunomide | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Moderate | 1 | [
[
[
1031,
24,
1510
]
],
[
[
1031,
24,
697
],
[
697,
24,
1510
]
],
[
[
1031,
24,
517
],
[
517,
63,
1510
]
],
[
[
1031,
63,
1684
],
[
1684,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Norgestr... |
DB00771 | DB08815 | 262 | 154 | [
"DDInter397",
"DDInter1104"
] | Clidinium | Lurasidone | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
262,
24,
154
]
],
[
[
262,
24,
100
],
[
100,
24,
154
]
],
[
[
262,
63,
1233
],
[
1233,
24,
154
]
],
[
[
262,
24,
103
],
[
103,
6... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine ... |
DB00620 | DB14006 | 175 | 972 | [
"DDInter1855",
"DDInter370"
] | Triamcinolone | Choline salicylate | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Moderate | 1 | [
[
[
175,
24,
972
]
],
[
[
175,
23,
771
],
[
771,
62,
972
]
],
[
[
175,
40,
1573
],
[
1573,
24,
972
]
],
[
[
175,
63,
176
],
[
176,
2... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
... | Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Choline salicylate
Triamcinolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate intera... |
DB00626 | DB01249 | 1,441 | 258 | [
"DDInter161",
"DDInter958"
] | Bacitracin | Iodixanol | Bacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.[A... | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Major | 2 | [
[
[
1441,
25,
258
]
],
[
[
1441,
25,
497
],
[
497,
1,
258
]
],
[
[
1441,
7,
5415
],
[
5415,
46,
258
]
],
[
[
1441,
21,
28719
],
[
28719,
... | [
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
],
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} (Compoun... | Bacitracin may lead to a major life threatening interaction when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Bacitracin (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Iodixanol (Compound)
Bacitracin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is cau... |
DB00471 | DB00559 | 201 | 152 | [
"DDInter1242",
"DDInter223"
] | Montelukast | Bosentan | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Moderate | 1 | [
[
[
201,
24,
152
]
],
[
[
201,
6,
6017
],
[
6017,
45,
152
]
],
[
[
201,
21,
29402
],
[
29402,
60,
152
]
],
[
[
201,
63,
1101
],
[
1101,
... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosentan"
]
],
[
[
"Montelukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",... | Montelukast (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bosentan (Compound)
Montelukast (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Bosentan (Compound)
Montelukast may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00349 | DB00792 | 902 | 832 | [
"DDInter401",
"DDInter1878"
] | Clobazam | Tripelennamine | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
902,
24,
832
]
],
[
[
902,
24,
100
],
[
100,
63,
832
]
],
[
[
902,
24,
649
],
[
649,
1,
832
]
],
[
[
902,
24,
1594
],
[
1594,
24... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
... | Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol ... |
DB00468 | DB01337 | 1,424 | 1,579 | [
"DDInter1557",
"DDInter1385"
] | Quinine | Pancuronium | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release. | Moderate | 1 | [
[
[
1424,
24,
1579
]
],
[
[
1424,
24,
1610
],
[
1610,
1,
1579
]
],
[
[
1424,
6,
4304
],
[
4304,
45,
1579
]
],
[
[
1424,
21,
28717
],
[
287... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pancuronium"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
],
[
"... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Pancuronium (Compound)
Quinine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Pancuronium (Compound)
Quinine (Compound) causes Flushing (Side Effect) and Flushing (Side Effe... |
DB00780 | DB01001 | 551 | 688 | [
"DDInter1440",
"DDInter1632"
] | Phenelzine | Salbutamol | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
551,
24,
688
]
],
[
[
551,
63,
874
],
[
874,
24,
688
]
],
[
[
551,
24,
455
],
[
455,
24,
688
]
],
[
[
551,
64,
1636
],
[
1636,
2... | [
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
... | Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salm... |
DB00559 | DB09049 | 152 | 1,135 | [
"DDInter223",
"DDInter1261"
] | Bosentan | Naloxegol | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Moderate | 1 | [
[
[
152,
24,
1135
]
],
[
[
152,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
152,
24,
971
],
[
971,
62,
1135
]
],
[
[
152,
63,
1424
],
[
1424,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
... | Bosentan may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a min... |
DB00526 | DB00580 | 1,555 | 311 | [
"DDInter1355",
"DDInter1910"
] | Oxaliplatin | Valdecoxib | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Moderate | 1 | [
[
[
1555,
24,
311
]
],
[
[
1555,
24,
663
],
[
663,
24,
311
]
],
[
[
1555,
63,
1560
],
[
1560,
24,
311
]
],
[
[
1555,
24,
1272
],
[
1272,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase an... |
DB00581 | DB03904 | 355 | 1,574 | [
"DDInter1018",
"DDInter1903"
] | Lactulose | Urea | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Moderate | 1 | [
[
[
355,
24,
1574
]
],
[
[
355,
63,
1230
],
[
1230,
24,
1574
]
],
[
[
355,
24,
657
],
[
657,
63,
1574
]
],
[
[
355,
23,
286
],
[
286,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Cit... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Urea
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may... |
DB00208 | DB01390 | 1,018 | 1,117 | [
"DDInter1804",
"DDInter1683"
] | Ticlopidine | Sodium bicarbonate | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Minor | 0 | [
[
[
1018,
23,
1117
]
],
[
[
1018,
21,
28882
],
[
28882,
60,
1117
]
],
[
[
1018,
23,
1220
],
[
1220,
23,
1117
]
],
[
[
1018,
24,
902
],
[
9... | [
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Ticlopidine",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature in... | Ticlopidine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sodium bicarbonate (Compound)
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can ... |
DB00350 | DB00425 | 1,214 | 558 | [
"DDInter1226",
"DDInter1970"
] | Minoxidil | Zolpidem | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Moderate | 1 | [
[
[
1214,
24,
558
]
],
[
[
1214,
6,
10522
],
[
10522,
45,
558
]
],
[
[
1214,
24,
407
],
[
407,
63,
558
]
],
[
[
1214,
63,
1648
],
[
1648,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
]
],
[
[
"Minoxidil",
"{u} (Compound) binds {v} (Gene)",
"PTGS1"
],
[
"PTGS1",
"{u} (Gene) is bound by {v} (Compound)",
... | Minoxidil (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Zolpidem (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem
Minoxidil may cause a moderate inter... |
DB00697 | DB01218 | 876 | 1,493 | [
"DDInter1821",
"DDInter852"
] | Tizanidine | Halofantrine | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
876,
25,
1493
]
],
[
[
876,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
876,
23,
112
],
[
112,
23,
1493
]
],
[
[
876,
24,
770
],
[
770,
... | [
[
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Tizanidine",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effe... | Tizanidine (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical eff... |
DB00630 | DB00798 | 1,485 | 1,132 | [
"DDInter42",
"DDInter815"
] | Alendronic acid | Gentamicin | Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Moderate | 1 | [
[
[
1485,
24,
1132
]
],
[
[
1485,
21,
28703
],
[
28703,
60,
1132
]
],
[
[
1485,
24,
361
],
[
361,
63,
1132
]
],
[
[
1485,
1,
963
],
[
963,... | [
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gentamicin"
]
],
[
[
"Alendronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect)... | Alendronic acid (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Gentamicin (Compound)
Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Gen... |
DB00543 | DB00771 | 87 | 262 | [
"DDInter82",
"DDInter397"
] | Amoxapine | Clidinium | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Moderate | 1 | [
[
[
87,
24,
262
]
],
[
[
87,
24,
1511
],
[
1511,
63,
262
]
],
[
[
87,
6,
7992
],
[
7992,
45,
262
]
],
[
[
87,
63,
19
],
[
19,
24,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
... | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Amoxapine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Clidinium (Compound)
Amoxapine may cause a ... |
DB00106 | DB09082 | 618 | 659 | [
"DDInter4",
"DDInter1934"
] | Abarelix | Vilanterol | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
618,
24,
659
]
],
[
[
618,
24,
1570
],
[
1570,
24,
659
]
],
[
[
618,
24,
927
],
[
927,
63,
659
]
],
[
[
618,
25,
1069
],
[
1069,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
... | Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encor... |
DB00662 | DB01174 | 717 | 697 | [
"DDInter1873",
"DDInter1442"
] | Trimethobenzamide | Phenobarbital | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
717,
24,
697
]
],
[
[
717,
24,
759
],
[
759,
1,
697
]
],
[
[
717,
63,
362
],
[
362,
1,
697
]
],
[
[
717,
63,
536
],
[
536,
40,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarb... |
DB01147 | DB09420 | 950 | 1,074 | [
"DDInter418",
"DDInter953"
] | Cloxacillin | Iodide I-123 | A semi-synthetic penicillin antibiotic which is a chlorinated derivative of [oxacillin]. | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
950,
24,
1074
]
],
[
[
950,
40,
339
],
[
339,
24,
1074
]
],
[
[
950,
63,
126
],
[
126,
24,
1074
]
],
[
[
950,
1,
790
],
[
790,
2... | [
[
[
"Cloxacillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Cloxacillin",
"{u} (Compound) resembles {v} (Compound)",
"Bacampicillin"
],
[
"Bacampicillin",
"{u} may cause... | Cloxacillin (Compound) resembles Bacampicillin (Compound) and Bacampicillin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Cloxacillin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that... |
DB00489 | DB09080 | 17 | 144 | [
"DDInter1704",
"DDInter1331"
] | Sotalol | Olodaterol | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Major | 2 | [
[
[
17,
25,
144
]
],
[
[
17,
25,
1011
],
[
1011,
24,
144
]
],
[
[
17,
24,
543
],
[
543,
24,
144
]
],
[
[
17,
64,
322
],
[
322,
24,
... | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olodaterol"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cau... | Sotalol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a mode... |
DB09036 | DB14443 | 812 | 987 | [
"DDInter1668",
"DDInter1931"
] | Siltuximab | Vibrio cholerae CVD 103-HgR strain live antigen | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
812,
24,
987
]
],
[
[
812,
63,
259
],
[
259,
24,
987
]
],
[
[
812,
64,
581
],
[
581,
24,
987
]
],
[
[
812,
25,
1259
],
[
1259,
2... | [
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Siltuximab may lead to a major life threatening interaction when taken with... |
DB01215 | DB14723 | 1,418 | 159 | [
"DDInter677",
"DDInter1026"
] | Estazolam | Larotrectinib | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1418,
24,
159
]
],
[
[
1418,
63,
222
],
[
222,
23,
159
]
],
[
[
1418,
24,
98
],
[
98,
24,
159
]
],
[
[
1418,
1,
481
],
[
481,
24... | [
[
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatre... |
DB00224 | DB00603 | 215 | 303 | [
"DDInter917",
"DDInter1137"
] | Indinavir | Medroxyprogesterone acetate | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Minor | 0 | [
[
[
215,
23,
303
]
],
[
[
215,
24,
167
],
[
167,
1,
303
]
],
[
[
215,
25,
1486
],
[
1486,
1,
303
]
],
[
[
215,
6,
8374
],
[
8374,
45... | [
[
[
"Indinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Medroxyprogesterone acetate"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Indinavir may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone (Compound) resemble... |
DB00570 | DB12130 | 147 | 1,017 | [
"DDInter1936",
"DDInter1094"
] | Vinblastine | Lorlatinib | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
147,
24,
1017
]
],
[
[
147,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
147,
25,
976
],
[
976,
24,
1017
]
],
[
[
147,
24,
1554
],
[
1554,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Vinblastine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may caus... |
DB00188 | DB05273 | 168 | 507 | [
"DDInter222",
"DDInter1638"
] | Bortezomib | Samarium (153Sm) lexidronam | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
168,
25,
507
]
],
[
[
168,
24,
248
],
[
248,
24,
507
]
],
[
[
168,
24,
270
],
[
270,
63,
507
]
],
[
[
168,
23,
1101
],
[
1101,
2... | [
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken w... |
DB03904 | DB04835 | 1,574 | 1,655 | [
"DDInter1903",
"DDInter1125"
] | Urea | Maraviroc | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Moderate | 1 | [
[
[
1574,
24,
1655
]
],
[
[
1574,
23,
1399
],
[
1399,
63,
820
],
[
820,
24,
1655
]
],
[
[
1574,
24,
643
],
[
643,
6,
8374
],
[
8374,
45,... | [
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Urea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
],
[
"Lit... | Urea may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc... |
DB00619 | DB00813 | 1,419 | 704 | [
"DDInter909",
"DDInter722"
] | Imatinib | Fentanyl | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Major | 2 | [
[
[
1419,
25,
704
]
],
[
[
1419,
23,
307
],
[
307,
1,
704
]
],
[
[
1419,
63,
194
],
[
194,
40,
704
]
],
[
[
1419,
25,
1322
],
[
1322,
... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"... | Imatinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Fentanyl (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Fentanyl (Compound)
Imatinib m... |
DB00661 | DB11986 | 122 | 484 | [
"DDInter1928",
"DDInter648"
] | Verapamil | Entrectinib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
122,
25,
484
]
],
[
[
122,
23,
466
],
[
466,
62,
484
]
],
[
[
122,
25,
1135
],
[
1135,
23,
484
]
],
[
[
122,
23,
222
],
[
222,
2... | [
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamid... | Verapamil may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Verapamil may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a m... |
DB01320 | DB14568 | 651 | 982 | [
"DDInter783",
"DDInter1000"
] | Fosphenytoin | Ivosidenib | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
651,
25,
982
]
],
[
[
651,
63,
112
],
[
112,
23,
982
]
],
[
[
651,
64,
168
],
[
168,
23,
982
]
],
[
[
651,
62,
1101
],
[
1101,
2... | [
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Met... | Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Fosphenytoin may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib ma... |
DB00346 | DB06176 | 472 | 1,342 | [
"DDInter44",
"DDInter1616"
] | Alfuzosin | Romidepsin | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
472,
24,
1342
]
],
[
[
472,
23,
112
],
[
112,
23,
1342
]
],
[
[
472,
24,
485
],
[
485,
24,
1342
]
],
[
[
472,
24,
1616
],
[
1616,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Alfuzosin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Penta... |
DB00860 | DB00962 | 891 | 1,639 | [
"DDInter1513",
"DDInter1957"
] | Prednisolone | Zaleplon | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Minor | 0 | [
[
[
891,
23,
1639
]
],
[
[
891,
6,
8374
],
[
8374,
45,
1639
]
],
[
[
891,
21,
29101
],
[
29101,
60,
1639
]
],
[
[
891,
63,
1324
],
[
1324,... | [
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zaleplon"
]
],
[
[
"Prednisolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Prednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zaleplon (Compound)
Prednisolone (Compound) causes Glaucoma (Side Effect) and Glaucoma (Side Effect) is caused by Zaleplon (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Tr... |
DB00279 | DB00783 | 1,152 | 1,438 | [
"DDInter1074",
"DDInter679"
] | Liothyronine | Estradiol | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Moderate | 1 | [
[
[
1152,
24,
1438
]
],
[
[
1152,
24,
1561
],
[
1561,
40,
1438
]
],
[
[
1152,
6,
16560
],
[
16560,
45,
1438
]
],
[
[
1152,
7,
13230
],
[
1... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Estradiol (Compound)
Liothyronine (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Estradiol (Compound)
Liothyronine (Compound) upregulates TIPARP (Gene) and TIPA... |
DB00674 | DB00916 | 1,516 | 112 | [
"DDInter802",
"DDInter1202"
] | Galantamine | Metronidazole | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Moderate | 1 | [
[
[
1516,
24,
112
]
],
[
[
1516,
6,
8374
],
[
8374,
45,
112
]
],
[
[
1516,
21,
28692
],
[
28692,
60,
112
]
],
[
[
1516,
63,
618
],
[
618,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Galantamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Galantamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound)
Galantamine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00804 | DB09488 | 1,507 | 103 | [
"DDInter543",
"DDInter23"
] | Dicyclomine | Acrivastine | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1507,
24,
103
]
],
[
[
1507,
24,
1405
],
[
1405,
24,
103
]
],
[
[
1507,
63,
85
],
[
85,
24,
103
]
],
[
[
1507,
62,
551
],
[
551,
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
... | Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Atropine... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.